Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
Z614982-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $99.90 | |
Z614982-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $259.90 | |
Z614982-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $399.90 | |
Z614982-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $679.90 | |
Z614982-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $929.90 | |
Z614982-100mg | 100mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,299.90 |
Synonyms | AC-35757 | FWL2263R77 | EXT-0914 | (4'R,6'S,7'S)-17'-fluoro-4',6'-dimethyl-13'-[(4S)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]spiro[1,3-diazinane-5,8'-5,15-dioxa-2,14-diazatetracyclo[8.7.0.02,7.012,16]heptadeca-1(17),10,12(16),13-tetraene]-2,4,6-trione | UNII-F |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | INHIBITOR |
Mechanism of action | DNA gyrase inhibitor |
Product Description |
Zoliflodacin (ETX0914;AZD0914) is a novel spiropyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor. Zoliflodacin has potent in vitro antibacterial activity against Gram-positive and Gram-negative organisms, including S. aureus with the MIC90 of 0.25 μg/mL.
|
ALogP | 1.3 |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | (4'R,6'S,7'S)-17'-fluoro-4',6'-dimethyl-13'-[(4S)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]spiro[1,3-diazinane-5,8'-5,15-dioxa-2,14-diazatetracyclo[8.7.0.02,7.012,16]heptadeca-1(17),10,12(16),13-tetraene]-2,4,6-trione |
---|---|
INCHI | InChI=1S/C22H22FN5O7/c1-8-7-33-21(32)28(8)17-12-4-11-5-22(18(29)24-20(31)25-19(22)30)16-10(3)34-9(2)6-27(16)14(11)13(23)15(12)35-26-17/h4,8-10,16H,5-7H2,1-3H3,(H2,24,25,29,30,31)/t8-,9+,10-,16+/m0/s1 |
InChi Key | ZSWMIFNWDQEXDT-ZESJGQACSA-N |
Canonical SMILES | CC1CN2C(C(O1)C)C3(CC4=CC5=C(C(=C42)F)ON=C5N6C(COC6=O)C)C(=O)NC(=O)NC3=O |
Isomeric SMILES | C[C@@H]1CN2[C@H]([C@@H](O1)C)C3(CC4=CC5=C(C(=C42)F)ON=C5N6[C@H](COC6=O)C)C(=O)NC(=O)NC3=O |
Alternate CAS | 1620458-09-4 |
PubChem CID | 76685216 |
MeSH Entry Terms | (2R,4S,4AS)-11-fluoro-2,4-dimethyl-8-((4S)-4-methyl-2-oxo-1,3-oxazolidin-3-yl)-1,2,4,4a-tetrahydro-2'H,6H-spiro((1,2)-oxazolo(4,5-g)(1,4)oxazino(4,3-a)quinoline-5,5'-pyrimidine)-2',4',6'(1'H,3'H)-trione;AZD-0914;AZD0914;ETX-0914;ETX0914;zoliflodacin |
Molecular Weight | 487.44 |
CAS Registry No. | 1620458-09-4 |
---|---|
PubChem CID | 76685216 |
ChEMBL Ligand | CHEMBL3544978 |
BindingDB Ligand | 139376 |
DrugBank Ligand | DB12817 |
Antibiotic DB | 1185 |
RCSB PDB Ligand | R8U |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
J2431567 | Certificate of Analysis | Sep 13, 2024 | Z614982 |
J2431574 | Certificate of Analysis | Sep 13, 2024 | Z614982 |
J2411571 | Certificate of Analysis | Sep 13, 2024 | Z614982 |
J2431562 | Certificate of Analysis | Sep 13, 2024 | Z614982 |
J2431563 | Certificate of Analysis | Sep 13, 2024 | Z614982 |
J2431564 | Certificate of Analysis | Sep 13, 2024 | Z614982 |
J2431565 | Certificate of Analysis | Sep 13, 2024 | Z614982 |
J2431566 | Certificate of Analysis | Sep 13, 2024 | Z614982 |
J2431568 | Certificate of Analysis | Sep 13, 2024 | Z614982 |
J2431569 | Certificate of Analysis | Sep 13, 2024 | Z614982 |
J2431570 | Certificate of Analysis | Sep 13, 2024 | Z614982 |
1. Basarab GS, Kern GH, McNulty J, Mueller JP, Lawrence K, Vishwanathan K, Alm RA, Barvian K, Doig P, Galullo V et al.. (2015) Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.. Sci Rep, 5 (13): (11827). [PMID:26168713] [10.1021/op500134e] |
2. Bradford PA, Miller AA, O'Donnell J, Mueller JP. (2020) Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of Neisseria gonorrheae, Including Multi-Drug-Resistant Isolates.. ACS Infect Dis, 6 (6): (1332-1345). [PMID:32329999] [10.1021/op500134e] |
3. Luckey A, Alirol E, Delhomme S, O'Donnell J, Bettiol E, Mueller J, O'Brien S, Gillon JY. (2023) Effect of food on the pharmacokinetics of zoliflodacin granules for oral suspension: Phase I open-label randomized cross-over study in healthy subjects.. Clin Transl Sci, 71 (13): (1755-70). [PMID:36824016] [10.1021/op500134e] |